Health alerts that sprouts are depleting remdesivir

More than 100 dead in armed clashes between Armenians and Azeris. What lies behind the Nagorno-Karabakh conflict VIDEO INFOGRAPHICS

The conflict continued last night between Azerbaijan and ethnic Armenians in the mountain enclave of Nagorno-Karabakh, the Azerbaijani Defense Ministry said on Tuesday.The ministry...

An expert predicts “chaos” in hospitals when flu season and coronavirus coincide

The counselor of the Italian Ministry of Health and a member of the council of the World Health Organization, Walter Ricciardi, affirmed this Tuesday...

Crisis in Venezuela: the opposition urged the Armed Forces to withdraw their support for Nicolás Maduro

He pointed out that "the regime is organizing for a new attack against the citizens" with the aim of staying in power. The Venezuelan opposition...

Hungary calls for the resignation of the vice-president of the European Commission

The frontal opposition of Hungary al compulsory distribution of refugees in the EU, their continuous disagreements with Brussels over attempts to control of...

Hungary and Poland will set up a joint rule of law institute

Taken aback for violating the rule of law, Poland and Hungary have decided to challenge the charge with a joint institute in the field....

The Spanish Agency for Medicines and Health Products (AEMPS), dependent on the Ministry of Health, has reported that the ‘available stock at the moment in Spain of remdesivir, the only authorized antiviral drug against COVID-19, “it will be sold out in the next few hours” due to the “increase in the number of cases”.

In a statement, the AEMPS explains that at the time of authorization, with the epidemiological situation in July, the laboratory that owns the drug guaranteed “a sufficient ‘stock’ of remdesivir in Spain to cover the needs until its production can be increased.” “However, with the increase in the number of cases, the available ‘stock’ is going to be exhausted in the next few hours,” the text acknowledges.

For this reason, the AEMPS, in collaboration with the hospital pharmacy services, will mobilize remdesivir left over from clinical trials, available in the participating hospitals, to attend to patients from all over the national territory who need it “until there is a new shipment of remdesivir next week. “

Next shipment next week

These shipments are part of the contract that the European Commission signed with the Gilead Pharmaceutical Company to guarantee access to remdesivir for 30,000 patients during the next months until the centralized purchase that will be effective in October. Spain received the first shipment (of three expected) last week. The second is scheduled for next week.

“However, the AEMPS is working so that it occurs as soon as possible and thus avoid tensions in the availability of the drug and the exchange of surplus drugs between hospitals,” they point out.

The AEMPS also assures that it is “in continuous and constant communication with the company on all matters related to remdesivir, to optimize treatments with the available medication and until production allows meeting the needs”.

The AEMPS has already published a series of Recommendations for Remdesivir Treatment of COVID-19 Patients in which a maximum duration of 5 days in hospitalized COVID-19 patients requiring supplemental oxygen, but not invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO).

Less panacea

Remdesivir, from which the United States has bought the fall production to stock up, has been shown to be very effective for a five-day application but not as effective if the treatment is extended to 10, according to a new study published in the journal of the medical association U.S.

The analysis, on 600 patients, denies that its effects reduce hospitalization time, although they do improve the general condition of the patient compared to other treatments but not so much.

Gilead, which is now releasing the study drug, is pending full approval from the US pharmaceutical regulator, the FDA.




Related Articles